Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer

Cancer Letters

Volumn 338, Issue 2, 2013, Pages 271-281

  Seo, Ju Hyeon ^a   Jung, Kyung Hee ^a   Son, Mi Kwon ^a   Yan, Hong Hua ^a   Ryu, Ye Lim ^a   Kim, Jinhee ^b   Lee, Jung Kyun ^b,c   Hong, Sungwoo ^b   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c Soomshinun Oriental Medical Clinic   (South Korea)

Author keywords

Angiogenesis; Apoptosis; HS 345; Pancreatic cancer; Tropomyosin related kinase A (TrkA)

Indexed keywords

ALPHA TROPOMYOSIN; CASPASE 3; ENZYME INHIBITOR; HS 345; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNODETECTION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

AGOUTI PACA; MUS;

ANGIOGENESIS; APOPTOSIS; HS-345; PANCREATIC CANCER; TROPOMYOSIN-RELATED KINASE A (TRKA);

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84881668008     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.002     Document Type: Article

References (38)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62:10-29.
2. Krejs G.J. Pancreatic cancer: epidemiology and risk factors. Dig. Dis. 2010, 28:355-358.
3. Link K.H., Gansauge F., Gorich J., Leder G.H., Rilinger N., Beger H.G. Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur. J. Surg. Oncol. 1997, 23:409-414.
4. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
5. Farrell T.J., Barbot D.J., Rosato F.E. Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer. Ann. Surg. 1997, 226:66-69.
6. Tauszig-Delamasure S., Yu L.Y., Cabrera J.R., Bouzas-Rodriguez J., Mermet-Bouvier C., Guix C., Bordeaux M.C., Arumae U., Mehlen P. The TrkC receptor induces apoptosis when the dependence receptor notion meets the neurotrophin paradigm. Proc. Natl. Acad. Sci. USA 2007, 104:13361-13366.
7. Lagadec C., Meignan S., Adriaenssens E., Foveau B., Vanhecke E., Romon R., Toillon R.A., Oxombre B., Hondermarck H., Le Bourhis X. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 2009, 28:1960-1970.
8. Zhu Z.W., Friess H., Wang L., Bogardus T., Korc M., Kleeff J., Buchler M.W. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clin. Cancer Res. 2001, 7:105-112.
9. Rasi G., Serafino A., Bellis L., Lonardo M.T., Andreola F., Zonfrillo M., Vennarecci G., Pierimarchi P., Sinibaldi Vallebona P., Ettorre G.M., Santoro E., Puoti C. Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma. World J. Gastroenterol. 2007, 13:4986-4995.
10. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 2004, 4:361-370.
11. Miknyoczki S.J., Lang D., Huang L., Klein-Szanto A.J., Dionne C.A., Ruggeri B.A. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int. J. Cancer 1999, 81:417-427.
12. A.A. Bapat, G. Hostetter, D.D. Von Hoff, H. Han, Perineural invasion and associated pain in pancreatic cancer, Nat Rev Cancer 11 (2011) 695-707.
13. Segal R.A. Selectivity in neurotrophin signaling: theme and variations. Annu. Rev. Neurosci. 2003, 26:299-330.
14. Huang E.J., Reichardt L.F. Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 2003, 72:609-642.
15. Zhang Y., Dang C., Ma Q., Shimahara Y. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer. Oncol. Rep. 2005, 14:161-171.
16. Hong J., Kim J.H., Seo K.H. Jung, and S.S. Hong, Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and antiangiogenic activities. J. Med. Chem. 2012, 55:5337-5349.
17. Lin Z.X., Hoult J.R., Raman A. Sulphorhodamine B assay for measuring proliferation of a pigmented melanocyte cell line and its application to the evaluation of crude drugs used in the treatment of vitiligo. J. Ethnopharmacol. 1999, 66:141-150.
18. Schneider M.B., Standop J., Ulrich A., Wittel U., Friess H., Andren-Sandberg A., Pour P.M. Expression of nerve growth factors in pancreatic neural tissue and pancreatic cancer. J. Histochem. Cytochem. 2001, 49:1205-1210.
19. Shabbir M., Stuart R. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin. Investig. Drugs 2010, 19:427-436.
20. Kaplan D.R., Miller F.D. Signal transduction by the neurotrophin receptors. Curr. Opin. Cell Biol. 1997, 9:213-221.
21. Yilmaz T., Jiffar T., de la Garza G., Lin H., Milas Z., Takahashi Y., Hanna E., MacIntyre T., Brown J.L., Myers J.N., Kupferman M.E. Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC. Cancer Biol. Ther. 2010, 10:644-653.
22. Islam O., Loo T.X., Heese K. Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways. Curr. Neurovasc Res. 2009, 6:42-53.
23. Miranda C., Fumagalli T., Anania M.C., Vizioli M.G., Pagliardini S., Pierotti M.A., Greco A. Role of STAT3 in in vitro transformation triggered by TRK oncogenes. PLoS ONE 2010, 5:e9446.
24. Romon R., Adriaenssens E., Lagadec C., Germain E., Hondermarck H., Le Bourhis X. Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol. Cancer 2010, 9:157.
25. Liu D., Zhang Y., Dang C., Ma Q., Lee W., Chen W. SiRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway. Oncol. Rep. 2007, 18:673-677.
26. Wu J. Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review). Anticancer Res. 1996, 16:2233-2239.
27. Tacconelli A., Farina A.R., Cappabianca L., Desantis G., Tessitore A., Vetuschi A., Sferra R., Rucci N., Argenti B., Screpanti I., Gulino A., Mackay A.R. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 2004, 6:347-360.
28. Riedel F., Gotte K., Bergler W., Hormann K. Inverse correlation of apoptotic and angiogenic markers in squamous cell carcinoma of the head and neck. Oncol. Rep. 2001, 8:471-476.
29. Onizuka S., Kawakami S., Taniguchi K., Fujioka H., Miyashita K. Pancreatic carcinogenesis: apoptosis and angiogenesis. Pancreas 2004, 28:317-319.
30. Jiang B.H., Rue E., Wang G.L., Roe R., Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271:17771-17778.
31. Nakamura K., Martin K.C., Jackson J.K., Beppu K., Woo C.W., Thiele C.J. Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res. 2006, 66:4249-4255.
32. Nakamura K., Tan F., Li Z., Thiele C.J. NGF activation of TrkA induces vascular endothelial growth factor expression via induction of hypoxia-inducible factor-1alpha. Mol. Cell. Neurosci. 2011, 46:498-506.
33. Blood C.H., Zetter B.R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta 1990, 1032:89-118.
34. Cantarella G., Lempereur L., Presta M., Ribatti D., Lombardo G., Lazarovici P., Zappala G., Pafumi C., Bernardini R. Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J. 2002, 16:1307-1309.
35. Raychaudhuri S.K., Raychaudhuri S.P., Weltman H., Farber E.M. Effect of nerve growth factor on endothelial cell biology: proliferation and adherence molecule expression on human dermal microvascular endothelial cells. Arch. Dermatol. Res. 2001, 293:291-295.
36. Steinle J.J., Granger H.J. Nerve growth factor regulates human choroidal, but not retinal, endothelial cell migration and proliferation. Auton. Neurosci. 2003, 108:57-62.
37. Rahbek U.L., Dissing S., Thomassen C., Hansen A.J., Tritsaris K. Nerve growth factor activates aorta endothelial cells causing PI3K/Akt- and ERK-dependent migration. Pflugers Arch. 2005, 450:355-361.
38. Lavault S., Leu-Semenescu S., Tezenas du Montcel S., Cochen de Cock V., Vidailhet M., Arnulf I. Does clinical rapid eye movement behavior disorder predict worse outcomes in Parkinson's disease?. J. Neurol. 2010, 257:1154-1159.